期刊文献+

银屑病和湿疹的生活质量调查及影响因素分析 被引量:4

Research of Quality of Life and Analysis of Impact Factors of Psoriasis and Eczema
下载PDF
导出
摘要 目的:调查银屑病及湿疹患者的生活质量并对其影响因素进行分析。方法:采用问卷调查的方式对本院门诊收治的200例银屑病患者及200例湿疹患者的生活质量进行调查,并对影响生活质量的因素进行回归分析。结果:湿疹组生活质量总分为(17.7±6.2)分,显著高于银屑病组的(14.8±5.0)分,比较差异有统计学意义(P<0.05);湿疹组的症状和情感、社交娱乐、治疗的得分均明显高于银屑病组,比较差异均有统计学意义(P<0.05)。经多因素分析发现:经济水平、复发情况、病情、文化水平是影响生活质量总分的因素(P<0.05)。结论:银屑病、湿疹患者生活质量水平较低,经济水平、复发情况、文化水平及病情是影响生活质量的因素。 Objective:To investigate the quality of life of patients with psoriasis and eczema and analyze its influencing factors.Method:A questionnaire survey was conducted to investigate the quality of life of 200 patients of psoriasis and 200 patients of eczema,and the factors affecting the quality of life were analyzed by regressionanalysis.Result:The total score of quality of life in the eczema group was(17.7±6.2)points,which was significantly higher than that of the psoriasis group(14.8±5.0)points,the difference was statistically significant(P〈0.05).The scores of symptoms and emotions,social entertainment and treatment of the eczema group were significantly higher than those of the psoriasis group,the differences were statistically significant(P〈0.05).The regression analysis showed that the level of economy,recurrence,disease and cultural level were the factors affecting the quality of life(P〈0.05).Conclusion:The quality of life in patients with psoriasis and eczema are relatively low.Economic level,recurrence,cultural level and disease are the factors that affect the quality of life.
出处 《中国医学创新》 CAS 2016年第10期61-64,共4页 Medical Innovation of China
基金 云浮市医药卫生科研立项课题(2014B53)
关键词 银屑病 湿疹 生活质量 影响因素 Psoriasis Eczema Quality of life Influence factors
  • 相关文献

参考文献15

  • 1林兰,吴世友,张雷.慢性湿疹患者生活质量状况及其影响因素分析[J].医学综述,2014,20(14):2673-2675. 被引量:14
  • 2彭科.银屑病患者208例生活质量调查研究[J].临床医学,2012,32(2):88-89. 被引量:4
  • 3Batalla A,Coto E,González-Lara L,et al.Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17Ers79877597 and psoriasis in a spanish cohort[J].J Dermatol Sci,2015,80(2):111-115.
  • 4Kim W B,Marinas J E,Qiang J,et al.Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice:a Canadian multicenter retrospective study[J].J Am Acad Dermatol,2015,73(2):237-241.
  • 5Krueger J G,Ferris L K,Menter A,et al.Anti-IL-23A m Ab BI 655066 for treatment of moderate-to-severe psoriasis:safety,efficacy,pharmacokinetics,and biomarker results of a singlerising-dose,randomized,double-blind,placebo-controlled trial[J].J Allergy Clin Immunol,2015,136(1):116-124.
  • 6Menting S P,Coussens E,Pouw M F,et al.Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis:a step toward personalized treatment[J].JAMADermatol,2015,151(6):616-622.
  • 7Mrowietz U,Leonardi C L,Girolomoni G,et al.Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis:a randomized,doubleblind,noninferiority trial(SCULPTURE)[J].J Am Acad Dermato,2015,73(1):27-36.
  • 8Bagel J,Levi E,Tyring S,et al.Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris[J].J Drugs Dermatol,2014,13(11):1374-1379.
  • 9Dhami S,Sheikh A.Estimating the prevalence of aero-allergy and/or food allergy in infants,children and young people with moderate-to-severe atopic eczema/dermatitis in primary care:multi-centre,cross-sectional study[J].J R Soc Med,2015,108(6):229-236.
  • 10Fowler J F,Graff O,Hamedani A G.A phase 3,randomized,double-blind,placebo-controlled study evaluating the efficacy and safety of alitretinoin(BAL4079)in the treatment of severe chronic hand eczema refractory to potent topical corticosteroid therapy[J].J Drugs Dermatol,2014,13(10):1198-1204.

二级参考文献45

  • 1邵长庚.我国银屑病的流行和防治现状[J].中华皮肤科杂志,1996,29(2):75-76. 被引量:72
  • 2Finaly AY,Khan GK.Dermatology life quality index(DLQI)-a simplepractical measure for routine clinical use[J].Clin Exp Dermatol,1994,19(3):210-216.
  • 3邓丹琪,李玉秋,王艳云,王敏华.十年住院湿疹病人临床资料分析[J].皮肤病与性病,2007,29(3):12-14. 被引量:5
  • 4Hjortsberg C, Bergman A, Bjarnason A,et al. Are treatment satisfaction,quality of life,and self-assessed diseaseseverity relevant parameters for patient registries? Experiences from Finnish and Swedish patients with psoriasis [J ]. Acta Derm Venereol, 2011,91 (4) :409-414.
  • 5Schoffski O,Augustin M, Prinz J,et al. Costs and quality of life in patients with moderate to severe plaque-type psoriasis in Germany:a multi-center study[J]. J Dtsch Dermatol Ges, 2007,5 (3) : 209-218.
  • 6Langham S,Langham J,Goertz HP,et al. Large-scale, prospective ,observational studies in patients with psoriasis and psoriatic arthritis:A systematic and critical review[J]. BMC Med Res Methodol, 2011 ( 11 ) : 32.
  • 7Hu SW,Holt EW,Husni ME, et al. Willingness-to-pay stated preferences for 8 health-related quality-of-life domains in psoriatic arthritis:a pilot study[J]. Semin Arthritis Rheum, 2010,39(5) : 384-397.
  • 8Delfino M Jr, Holt EW,Taylor CR,et al. Willingness-to- pay stated preferences for 8 health-related quality-of-life domains in psoriasis:a pilot study[J]. J Am Acad Dermatol, 2008,59 (3) : 439-447.
  • 9Tbyssen JP, Johansen JD, Linneberg A, et al. The epidemiology of hand eczema in the general population- prevalence and main findings[J]. Contact Dermatitis, 2010,62(2) :75-87.
  • 10Femandez-Penas P,Jones-Caballero M, Espallardo O, et al. Comparison of Skindex-29,Dermatology Life Quality Index,Psoriasis Disability Index and Medical Outcome Study Short Form 36 in patients with mild to severe psoriasis[J]. Br J Dermatol,2012,166(4) :884-887.

共引文献30

同被引文献57

引证文献4

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部